Role of Neoadjuvant Chemotherapy in Rectal Cancer: Interpretation of the EXPERT Study
- 1 October 2006
- journal article
- other
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 24 (28) , 4664-4665
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Intergroup RTOG 98–11: A phase III randomized study of 5-fluorouracil (5-FU), mitomycin, and radiotherapy versus 5-fluorouracil, cisplatin and radiotherapy in carcinoma of the anal canalJournal of Clinical Oncology, 2006
- Scheduling of Radiation and Chemotherapy for Limited-Stage Small-Cell Lung Cancer: Repopulation As a Cause of Treatment Failure?Journal of Clinical Oncology, 2006
- Neoadjuvant Capecitabine and Oxaliplatin Followed by Synchronous Chemoradiation and Total Mesorectal Excision in Magnetic Resonance Imaging–Defined Poor-Risk Rectal CancerJournal of Clinical Oncology, 2006
- Can histopathologic assessment of circumferential margin after preoperative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for 3-year disease-free survival?International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2005
- 608 ORAL An international phase II study of Capecitabine, Oxaliplatin, Radiotherapy and Excision (CORE) in patients with MRI-defined locally advanced rectal adenocarcinoma. interim resultsEuropean Journal of Cancer Supplements, 2005
- Socrates phase II study results: Capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (RT) in patients (pts) with locally advanced rectal cancer (LARC)Journal of Clinical Oncology, 2005
- Phase I Trial of Capecitabine and Weekly Irinotecan in Combination With Radiotherapy for Neoadjuvant Therapy of Rectal CancerJournal of Clinical Oncology, 2005
- Phase I/II Trial of Capecitabine, Oxaliplatin, and Radiation for Rectal CancerJournal of Clinical Oncology, 2003